Allogene Therapeutics (NASDAQ:ALLO) Posts Quarterly Earnings Results

Allogene Therapeutics (NASDAQ:ALLO) released its quarterly earnings results on Thursday. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06, Zacks reports.

Allogene Therapeutics Stock Performance

Shares of ALLO opened at $1.89 on Friday. The company has a market cap of $396.28 million, a price-to-earnings ratio of -1.21 and a beta of 1.02. Allogene Therapeutics has a 52-week low of $1.32 and a 52-week high of $4.89. The stock has a fifty day moving average price of $1.95 and a two-hundred day moving average price of $2.33.

Analyst Upgrades and Downgrades

ALLO has been the subject of a number of recent analyst reports. William Blair reissued an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th. Piper Sandler cut their price objective on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Finally, Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a research report on Friday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.40.

Insiders Place Their Bets

In related news, EVP Zachary Roberts sold 27,199 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $1.78, for a total value of $48,414.22. Following the completion of the transaction, the executive vice president now owns 488,054 shares of the company’s stock, valued at approximately $868,736.12. This trade represents a 5.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Timothy L. Moore sold 14,746 shares of the firm’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $1.71, for a total transaction of $25,215.66. Following the completion of the sale, the insider now owns 250,713 shares of the company’s stock, valued at $428,719.23. This trade represents a 5.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 52,710 shares of company stock valued at $92,125. 24.30% of the stock is currently owned by corporate insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).